A Phase 2, Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Long-Acting Lenacapavir in Combination With an Optimized Background Regimen in Treatment-experienced Adolescents and Children With HIV-1
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 31 Dec 2024 New trial record